GLI1 and neoplasm: For instance, pharmacological inhibition of DYRK1B has been reported to repress GLI expression downstream of SMO and subsequent in vivo tumor growth of both SMOi-sensitive and resistant pancreatic cancer cells (Gruber et al., 2016).